摘要
氟维司群(fulvestrant)是一种选择性雌激素受体下调剂,能特异性结合雌激素受体(estrogen receptor,ER),抑制其下游靶基因的转录并促进ER蛋白的快速降解。随着氟维司群在乳腺癌内分泌治疗中的广泛应用,耐药现象逐步突显。探索氟维司群的耐药机制、靶向机制中的核心分子是突破治疗瓶颈、改善预后的关键。本文将就氟维司群的耐药机制及其联合用药等新治疗方案的研究进展进行综述。
Fulvestrant is a selective estrogen receptor degrader(SERD),that can specifically bind to estrogen receptor(ER),block ER transcription activity,and induce the degradation of ER protein.However,along with its widespread use in breast cancer endocrine therapy,drug resistance does gradually develop.A better understanding of mechanisms on fulvestrant resistance and the exploration on precise targeted therapy is the key to breaking through treatment bottlenecks and subsequently improving the prognosis of patients.Here,we review research advances in the potential mechanisms of fulvestrant resistance and outline promising approaches such as combination therapy to overcome the resistance.
作者
徐丹妮
张巍(综述)
牛昀(审校)
Danni Xu;Wei Zhang;Yun Niu(Department of Breast Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Breast Cancer Prevention and Therapy,Tianjin 300060,China;Department of Anatomy and Histology,School of Basic Medical Sciences,Tianjin Medical University,Tianjin 300070,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第11期586-589,共4页
Chinese Journal of Clinical Oncology
关键词
乳腺癌
内分泌治疗
氟维司群
选择性雌激素受体下调剂
耐药性
breast cancer
endocrine therapy
fulvestrant
selective estrogen receptor degrader(SERD)
drug resistance
